Cargando…
Tocilizumab in COVID-19 management: addressing time of starting treatment
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BMJ Publishing Group
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9986926/ https://www.ncbi.nlm.nih.gov/pubmed/34992089 http://dx.doi.org/10.1136/ejhpharm-2021-003149 |
| _version_ | 1784901272154931200 |
|---|---|
| author | Khiali, Sajad Entezari-Maleki, Taher |
| author_facet | Khiali, Sajad Entezari-Maleki, Taher |
| author_sort | Khiali, Sajad |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9986926 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | BMJ Publishing Group |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-99869262023-03-07 Tocilizumab in COVID-19 management: addressing time of starting treatment Khiali, Sajad Entezari-Maleki, Taher Eur J Hosp Pharm PostScript BMJ Publishing Group 2023-03 2022-01-06 /pmc/articles/PMC9986926/ /pubmed/34992089 http://dx.doi.org/10.1136/ejhpharm-2021-003149 Text en © European Association of Hospital Pharmacists 2023. No commercial re-use. See rights and permissions. Published by BMJ. https://bmj.com/coronavirus/usageThis article is made freely available for personal use in accordance with BMJ’s website terms and conditions for the duration of the covid-19 pandemic or until otherwise determined by BMJ. You may use, download and print the article for any lawful, non-commercial purpose (including text and data mining) provided that all copyright notices and trade marks are retained. |
| spellingShingle | PostScript Khiali, Sajad Entezari-Maleki, Taher Tocilizumab in COVID-19 management: addressing time of starting treatment |
| title | Tocilizumab in COVID-19 management: addressing time of starting treatment |
| title_full | Tocilizumab in COVID-19 management: addressing time of starting treatment |
| title_fullStr | Tocilizumab in COVID-19 management: addressing time of starting treatment |
| title_full_unstemmed | Tocilizumab in COVID-19 management: addressing time of starting treatment |
| title_short | Tocilizumab in COVID-19 management: addressing time of starting treatment |
| title_sort | tocilizumab in covid-19 management: addressing time of starting treatment |
| topic | PostScript |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9986926/ https://www.ncbi.nlm.nih.gov/pubmed/34992089 http://dx.doi.org/10.1136/ejhpharm-2021-003149 |
| work_keys_str_mv | AT khialisajad tocilizumabincovid19managementaddressingtimeofstartingtreatment AT entezarimalekitaher tocilizumabincovid19managementaddressingtimeofstartingtreatment |